🔬🩸 Hematology Updates: Blenrep Combinations, CAR-T Breakthroughs, and Global Therapy Approvals
From Japan’s myeloma advances to breakthrough CAR-T responses and first-in-class therapies for PNH and hemophilia—this week’s hematology roundup delivers the latest global milestones transforming blood disorder care and blood cancer innovation.
💡 Key Highlights This Week:
✅ Blenrep-based regimens approved in Japan for relapsed/refractory multiple myeloma with survival benefit and no confirmed permanent vision loss
✅ FDA ODAC supports Darzalex Faspro for high-risk smoldering multiple myeloma, potentially shifting care from “watch and wait” to early intervention
🧪 Regeneron’s linvoseltamab shows 90 percent ORR and 76 percent CR in early combination trials with carfilzomib
🧠 PeproMene’s BAFF-R CAR-T achieves 100 percent complete response in heavily pretreated follicular lymphoma patients, with no CRS or neurotoxicity
🇨🇳 InnoCare’s Minjuvi becomes China’s first CD19-targeted therapy approved for relapsed/refractory DLBCL
🧪 Columvi + GemOx delivers 41 percent overall survival improvement in STARGLO trial; NCCN adds as Category 1 regimen
⏱️ Two-year STARGLO follow-up confirms long-term durability: median OS not reached; 89 percent of CR patients alive at one year
🇪🇺 CHMP backs Autolus’ obe-cel for adult relapsed/refractory B-ALL with 76.6 percent CR/CRi and low severe toxicity in the FELIX trial
🇹🇼 PiaSky approved in Taiwan as the first subcutaneous PNH therapy; effective even in C5 mutation populations
🌟 NovelMed’s Ruxoprubart delivers best-in-class Phase II efficacy in PNH with no adverse events and once-weekly SC dosing
👶 FDA approves Bayer’s Jivi for pediatric hemophilia A with flexible dosing backed by Alfa-PROTECT & PROTECT Kids trials
🇬🇧 NICE approves marstacimab as UK’s first weekly subcutaneous treatment for severe hemophilia B, targeting TFPI
🎯 Whether you’re tracking global hematology approvals, next-gen immunotherapies, or emerging PNH and hemophilia solutions—this update gives you the key insights to stay informed and ahead.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on blood cancers, cell therapies, and rare hematologic breakthroughs.
#Hematology #MultipleMyeloma #CAR_T #PNH #DLBCL #Hemophilia #BCellALL #Darzalex #Columvi #Blenrep #BiotechNews #ClinicalTrials #LucidQuest #PharmaInnovation #BloodCancer #CellTherapy #HealthcareUpdates